Aptar (ATR) Q3 2026 earnings review
Aptar's sales accelerate, but factory costs squeeze its profit
Aptar, a maker of medicine sprayers, lotion pumps and bottle caps, sped up its sales growth while its profit margins kept shrinking. Underlying sales grew 5% as strong demand for drink caps and perfume pumps offset the final quarter of inventory cuts by emergency-medicine customers. However, manufacturing costs rose faster than sales, and the Russian government seized its local unit, taking $30 million in cash. New chief executive Gael Touya forecast a 17% rebound in fourth-quarter profit per share excluding one-offs at the middle of the range by our math.
| Sales from businesses owned a year ago | +5% +1% last quarter |
|---|---|
| Profit per share, excluding one-offs | $1.52 -6% from a year ago at comparable FX |
| Consolidated Adjusted EBITDA margin | 21.3% -1.9 percentage points from a year ago |
| Q4 profit per share outlook | $1.39–1.47 middle of the range: +17% from a year ago |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stronger consumer sales and the end of the emergency-medicine drag were offset by worsening factory margins in Beauty. Last quarter, management said catching up on raw-material price increases would lift Beauty margins in the third quarter, but those margins fell to 11.4% on ongoing North American factory trouble.
The question now is whether the fourth-quarter profit rebound comes from genuine operational repair or just an easy comparison against last year's weak fourth quarter and a lower tax rate. Either Pharma returns to its 8% underlying pace and Beauty margins recover, or North American factory costs keep eating into the revenue gains. Fourth-quarter segment margins and Touya's plan for North America will settle it.
🐂 Bull Case
Consumer Packaging Accelerated to High Single Digits
Aptar makes dispensing pumps, sprays and caps for medicine, cosmetics and food. For three quarters, weak consumer demand and lower raw-material prices held back its two consumer divisions, Beauty and Closures. In the third quarter, new chief executive Gael Touya said both divisions picked up speed, "where innovation in beverage dispensing continues to gain momentum".
- Closures underlying sales: up 11% from a year ago, after 4% growth in the second quarter
- Beauty underlying sales: up 8% from a year ago, up from 1% last quarter
- Total underlying sales: up 5% from a year ago, the fastest pace in a year
This matters because the company no longer relies on its pharmaceutical division alone for growth. Bottled water, drink concentrates, sauces and luxury perfume pumps all grew at the same time, although passing higher plastic costs on to customers accounted for part of the revenue gain.
What to watch: the volume vs price breakdown in the quarterly filing. If volume drove most of the 11% Closures gain and 8% Beauty gain, the consumer recovery is real rather than just raw-material inflation.
Drug Delivery Destocking Ends as Predicted
All year, a drop in orders for emergency naloxone nasal sprays has hidden growth in the rest of Aptar's pharmaceutical business. In the third quarter, overall Pharma sales from businesses owned a year ago rose 1%, but grew 8% without the emergency-medicine drop. Demand grew across central nervous system and lung treatments, nasal decongestants, eye care, and rubber parts for injectable GLP-1 weight-loss drugs.
Touya said the fourth quarter will grow "without the headwind from emergency medicine destocking". That matches the schedule management laid out at the start of the year and backs up its fourth-quarter profit outlook, which points to a 17% rise in earnings per share excluding one-offs at the middle of the range by our math.
What to watch: fourth-quarter Pharma underlying sales growth. With the inventory work-down over, a reading near the 8% underlying pace would prove the rest of the drug-delivery portfolio can carry the division.
🐻 Bear Case
Beauty Margin Fell Despite Price Catch-Up
Last quarter, management blamed a 0.8 to 0.9 percentage-point drop in Beauty profit margins on a delay in passing higher resin costs to customers, and said that delay would clear up in the third quarter. In the third quarter, Aptar said "pass throughs of higher input costs also contributed positively" to Beauty's 8% underlying sales growth, yet the division's Adjusted EBITDA margin (operating profit before depreciation, excluding one-offs) still fell 0.7 percentage points from a year ago to 11.4%.
Across the whole group, the cost of making products rose by 1.2 percentage points of revenue by our math, and selling and overhead costs rose by 0.2 percentage points. Beauty's margin even slipped from 12.2% in the second quarter because of worse product mix and "ongoing challenges in North American operations". Closures margin also fell 0.6 percentage points to 15.5% because passing through raw-material costs adds revenue without adding profit.
What to watch: any concrete restructuring plan or plant fix for North American Beauty on the conference call. Until Touya sets a target and a date, higher sales in the consumer divisions are not turning into higher margins.
Cash Returns Exceed Free Cash Flow as Debt Costs Rise
Aptar continues to return more cash to shareholders than its operations generate after factory spending, while its borrowing costs climb. Over the first nine months of 2026, the dispenser maker paid out $272 million in buybacks and dividends against $198 million of free cash flow, or 138% of its cash generation by our math, and raised the quarterly dividend by 2 cents to $0.50 per share.
It slowed buybacks to $30 million in the third quarter from $50 million in the second and $100 million in the first. Even so, losing $30 million of cash in Russia and paying out more than free cash flow left net debt 8% higher than at year-end at $1.16 billion by our math, pushing third-quarter interest expense up 17% from a year ago to $15.8 million.
What to watch: fourth-quarter share repurchases and year-end net debt. Slowing buybacks for a second straight quarter suggests the new chief executive may prioritise debt reduction over stock repurchases.
Risks this quarter didn't answer
Several standing concerns cannot be checked from the earnings release alone or received no new update this quarter.
- Injectables growth rate: the release noted demand for GLP-1 and biologics parts, but the exact percentage growth rate awaits the quarterly filing's market table.
- Special legal costs: Aptar excluded another $3.1 million ($10.9 million year-to-date) of legal bills for its trade-secret and antitrust disputes with ARS Pharmaceuticals and patent cases with Nemera, a cost that has run for six straight quarters.
- Emergency-medicine dollar base and oral weight-loss pills: management still does not disclose dollar sales for emergency sprays, and long-term substitution from injectable GLP-1 drugs to oral pills remains untested.
👓 Other Themes
Russian Subsidiary Seizure Cost $60 Million
Aptar removed its Russian unit from its accounts after a "governmental decree placing the subsidiary under external administration" took away control. The seizure caused a $60.4 million after-tax loss ($0.94 per share), including $30 million of cash held in Russia, and cut reported sales growth by about 1 percentage point. Aptar excluded the Russian unit from both years in its underlying sales and adjusted profit numbers.
💲 Other KPIs
Free cash flow — operating cash flow minus factory spending — fell 13.7% from a year ago in the third quarter, though it more than doubled from $45.9 million in the second quarter. For the first nine months, cash generation dipped 4.0% to $197.8 million as higher inventory and customer receivables tied up $158.4 million of working capital.
Average diluted shares fell 3.7% from a year ago and 0.1% from last quarter after the packaging group bought back 234 thousand shares for $30 million during the period. Year-to-date repurchases of $180 million have cushioned per-share profit by nearly 4 percentage points during an operational earnings dip.
🔮 Guidance
New. The plan calls for fourth-quarter profit per share excluding one-offs of $1.43 at the middle of the range, up 17.2% from $1.22 a year ago at comparable exchange rates by our math. That puts full-year adjusted profit at $5.56 per share by our math, down 4.5%. Last year's fourth quarter was an easy comparison when margins dropped. If the four-quarter average beat of 2.2% holds, Q4 would reach $1.46 by our math.
New. The fourth-quarter outlook assumes a tax rate of 18.5% at the middle of the range, down from 23.4% in the third quarter and 0.9 percentage points below last year's 19.4% fourth-quarter adjusted tax rate. That lower tax rate provides a boost to fourth-quarter earnings per share compared with the first three quarters of 2026.
❓ Key Questions
Why did Beauty margins fall after resin prices caught up?
Last quarter management said an 0.8 to 0.9 percentage-point drag from delayed resin price pass-throughs would clear up in Q3. Pass-throughs helped Q3 sales, yet Beauty's margin dropped from 12.2% in Q2 to 11.4%. How large was the North American operational drag?
How fast did injectable drug components grow in Q3?
Growth in rubber parts for injectable medicines slowed from 24% in Q4 2025 to 9% in Q2 2026. The release omitted the market growth table, leaving investors waiting for the 10-Q filing to see if GLP-1 and biologics demand sped up or slowed further.
Did full-year factory spending and depreciation plans change?
In prior quarters Aptar forecast $260–280 million of capital spending and $310–320 million of depreciation and amortization for 2026. Nine-month spending is $192 million and depreciation is $231 million; did the Russian seizure alter the full-year numbers?
What is the plan and cost to fix North American Beauty?
Gael Touya took over as chief executive on September 1 and cited ongoing North American operational issues in Beauty. Will fixing those plants require a new restructuring charge or footprint closure, and when will margins return to the mid-teens?